Palvella Therapeutics (PVLA) Cash from Investing Activities (2014 - 2026)
Palvella Therapeutics (PVLA) reported Cash from Investing Activities of -$55.4 million for Q1 2026, down 39142.25% on a QoQ basis from $142000.0 in Q3 2024.
Palvella Therapeutics (PVLA) has 12 years of Cash from Investing Activities data on file, last reported at -$55.4 million in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$55.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.1 million (down 569.36% YoY) and the FY2023 annual result came in at $12.0 million, up 156.52% from the prior year.
- Cash from Investing Activities eased to -$55.4 million in Q1 2026 per PVLA's latest filing, from $142000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $11.9 million in Q1 2023 and bottomed at -$55.4 million in Q1 2026.
- The 4-year median for Cash from Investing Activities is $624500.0 (2022), against an average of -$4.4 million.
- Peak annual rise in Cash from Investing Activities reached 1662.86% in 2022, while the deepest fall reached 60428.57% in 2022.
- Tracing PVLA's Cash from Investing Activities over 4 years: stood at $1.1 million in 2022, then jumped by 211.56% to $3.4 million in 2023, then slumped by 95.88% to $142000.0 in 2024, then slumped by 39142.25% to -$55.4 million in 2026.
- Per Business Quant, the three latest PVLA Cash from Investing Activities figures stand at -$55.4 million (Q1 2026), $142000.0 (Q3 2024), and $2.2 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -55.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.44 Mn |
| Mar 31, 2026 | -55.44 Mn |
| Sep 30, 2024 | 142,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | 3.45 Mn |
| Dec 31, 2023 | 3.45 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Jun 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | -1.37 Mn |
| Mar 31, 2023 | 11.90 Mn |
| Mar 31, 2023 | 11.90 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 5.47 Mn |
| Sep 30, 2022 | 5.47 Mn |
| Jun 30, 2022 | -10.87 Mn |
| Jun 30, 2022 | -10.87 Mn |
| Mar 31, 2022 | -16.95 Mn |
| Mar 31, 2022 | -16.95 Mn |
| Dec 31, 2021 | -342,000.00 |
| Dec 31, 2021 | -342,000.00 |
| Sep 30, 2021 | -350,000.00 |
| Sep 30, 2021 | -350,000.00 |
| Jun 30, 2021 | -229,000.00 |
| Jun 30, 2021 | -229,000.00 |
| Mar 31, 2021 | -28,000.00 |
| Mar 31, 2021 | -28,000.00 |
| Dec 31, 2020 | 14.85 Mn |
| Dec 31, 2020 | 14.85 Mn |
| Sep 30, 2020 | 18.35 Mn |
| Sep 30, 2020 | 18.35 Mn |
| Jun 30, 2020 | 5.60 Mn |
| Jun 30, 2020 | 5.60 Mn |
| Mar 31, 2020 | 414,000.00 |
| Mar 31, 2020 | 414,000.00 |
| Dec 31, 2019 | -1.88 Mn |
| Dec 31, 2019 | -1.88 Mn |
| Sep 30, 2019 | 4.12 Mn |
| Sep 30, 2019 | 4.12 Mn |
| Jun 30, 2019 | 12.91 Mn |
| Jun 30, 2019 | 12.91 Mn |
| Mar 31, 2019 | -5.32 Mn |
| Mar 31, 2019 | -5.32 Mn |
| Dec 31, 2018 | -5.22 Mn |
| Dec 31, 2018 | -5.22 Mn |
| Sep 30, 2018 | 53.40 Mn |
| Sep 30, 2018 | 53.40 Mn |
| Jun 30, 2018 | -48.76 Mn |
| Jun 30, 2018 | -48.76 Mn |
| Mar 31, 2018 | -8.29 Mn |
| Mar 31, 2018 | -8.29 Mn |
| Dec 31, 2017 | -44.74 Mn |
| Dec 31, 2017 | -44.74 Mn |
| Sep 30, 2017 | -289,000.00 |
| Sep 30, 2017 | -289,000.00 |
| Jun 30, 2017 | -663,000.00 |
| Jun 30, 2017 | -663,000.00 |
| Mar 31, 2017 | -179,000.00 |
| Mar 31, 2017 | -179,000.00 |
| Dec 31, 2016 | -237,294.00 |
| Dec 31, 2016 | -237,294.00 |
| Sep 30, 2016 | -198,098.00 |
| Sep 30, 2016 | -198,098.00 |
| Jun 30, 2016 | -56,689.00 |
| Jun 30, 2016 | -56,689.00 |
| Mar 31, 2016 | -67,919.00 |
| Mar 31, 2016 | -67,919.00 |
| Dec 31, 2015 | -351,482.00 |
| Dec 31, 2015 | -351,482.00 |
| Sep 30, 2015 | -194,979.00 |
| Sep 30, 2015 | -194,979.00 |
| Jun 30, 2015 | -33,638.00 |
| Jun 30, 2015 | -33,638.00 |
| Mar 31, 2015 | -40,648.00 |
| Mar 31, 2015 | -40,648.00 |
| Sep 30, 2014 | -14,311.00 |
| Sep 30, 2014 | -14,311.00 |
| Jun 30, 2014 | -4,961.00 |
| Jun 30, 2014 | -4,961.00 |
| Mar 31, 2014 | -1,768.00 |
| Mar 31, 2014 | -1,768.00 |